Abstract
To the Editor: Tumor necrosis factor alfa (TNFα) inhibitors are potent immunomodulators and provide options for treating a number of conditions including psoriasis and rheumatoid arthritis. Reported side effects from these agents include drug-induced autoimmune disorders.1 The induction of antinuclear antibodies (ANA), anti-dsDNA antibodies, or both has been observed in approximately 4% of patients treated with TNFα inhibitors.1 Also, drug-induced lupus erythematosus (LE) has been associated with both infliximab and etanercept.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
